Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 4/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 5/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25323662 | 1.00 | PRMT5 (0.39) | PRMT5WDR77RIPK1TP53MDM2 | |
| SCHEMBL25322165 | 0.96 | PRMT5 (0.36) | PRMT5WDR77RIPK1TP53MDM2 | |
| SCHEMBL30551045 | 0.96 | PRMT5 (0.36) | PRMT5WDR77RIPK1TP53MDM2 | |
| SCHEMBL25325890 | 0.95 | PRMT5 (0.38) | PRMT5WDR77RIPK1TP53MDM2 | |
| SCHEMBL25320105 | 0.89 | PRMT5 (0.35) | PRMT5WDR77 | |
| SCHEMBL25322535 | 0.89 | KMT2A (0.41) | PRMT5WDR77 | |
| SCHEMBL24365768 | 0.89 | KMT2A (0.41) | PRMT5WDR77 | |
| SCHEMBL24366899 | 0.89 | PRMT5 (0.43) | PRMT5WDR77RIPK1 | |
| SCHEMBL25321812 | 0.89 | RIPK1 (0.46) | PRMT5WDR77RIPK1 | |
| SCHEMBL25321815 | 0.89 | RIPK1 (0.46) | PRMT5WDR77RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | PRMT5 562/4885WDR77 1925/4885RIPK1 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.